TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 04/25/24

2024-04-25 08:30:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

2024-04-25 08:00:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

2024-04-23 14:22:14 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Sentia Medical Sciences and Neurocrine Biosciences extend research colla...

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire SAVITRI ™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MA...

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK...

− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. ...

2024-04-09 10:48:41 ET Summary Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome market is expected to reach $1 billion by 2036. Re...

FY23 Investment Brings Program Total to Nearly $55 Million, Welcoming Eight New Grant Partners Company Continues to Advance Equity in Under-Resourced Communities with a Focus on Nutrition and STEM Education Takeda Publishes its Annual U.S. Community Impact Report Highlighting Prog...

2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...

2024-04-05 13:53:08 ET More on Ovid Therapeutics Seeking Alpha’s Quant Rating on Ovid Therapeutics Historical earnings data for Ovid Therapeutics Financial information for Ovid Therapeutics Read the full article on Seeking Alpha For further det...